Patch Testing in Individuals With Diabetes Using Medical Devices. Part 2—Contact Allergy to Medical Device Allergens and New Patch Test Recommendations
(2026) In Contact Dermatitis- Abstract
Background: Previous studies on contact allergy to diabetes medical devices (MDs) are based on patients referred for patch testing due to suspected allergic contact dermatitis. Objectives: To present real-world data on contact allergy to MD allergens among diabetes MD users. To suggest a MD patch test series. Methods: Adults with type 1 diabetes using diabetes MDs followed up at two endocrinology departments were invited to be patch tested with a novel MD patch test series. Results: Of the 204 participants (114 with skin rash to diabetes MDs, 90 without), 16.2% were positive to allergens found in diabetes MDs. The prevalence was significantly higher in those with skin rash to diabetes MDs versus without (28.1% vs. 1.1%; adjusted p-value... (More)
Background: Previous studies on contact allergy to diabetes medical devices (MDs) are based on patients referred for patch testing due to suspected allergic contact dermatitis. Objectives: To present real-world data on contact allergy to MD allergens among diabetes MD users. To suggest a MD patch test series. Methods: Adults with type 1 diabetes using diabetes MDs followed up at two endocrinology departments were invited to be patch tested with a novel MD patch test series. Results: Of the 204 participants (114 with skin rash to diabetes MDs, 90 without), 16.2% were positive to allergens found in diabetes MDs. The prevalence was significantly higher in those with skin rash to diabetes MDs versus without (28.1% vs. 1.1%; adjusted p-value < 0.001). For allergens found in diabetes MDs, the highest contact allergy rates were seen to isobornyl acrylate (10.3%), N,N-dimethylacrylamide (4.9%), 2-hydroxyethyl acrylate (3.4%), and dicyclohexylmethane-4,4′-diisocyanate (2.9%). Conclusions: Among diabetes MD users, the prevalence of contact allergy to MD allergens was remarkably high. 2-hydroxyethyl acrylate has not previously been reported as a culprit allergen in diabetes MDs, which underlines the importance of repeated chemical analyses and continuous update of the MD series. A better prevention of MD-related contact allergies is called for.
(Less)
- author
- Ulriksdotter, Josefin
LU
; Mowitz, Martin
LU
; Sukakul, Thanisorn
LU
; Bruze, Magnus
LU
; Hamnerius, Nils
LU
and Svedman, Cecilia
LU
- organization
- publishing date
- 2026
- type
- Contribution to journal
- publication status
- epub
- subject
- keywords
- contact allergy, continuous glucose monitoring, insulin infusion systems, type 1 diabetes
- in
- Contact Dermatitis
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:41936552
- scopus:105034863602
- ISSN
- 0105-1873
- DOI
- 10.1111/cod.70149
- language
- English
- LU publication?
- yes
- additional info
- Publisher Copyright: © 2026 The Author(s). Contact Dermatitis published by John Wiley & Sons Ltd.
- id
- 41afe453-61f2-46a8-9009-1e145bccb391
- date added to LUP
- 2026-06-18 10:10:17
- date last changed
- 2026-06-19 03:18:21
@article{41afe453-61f2-46a8-9009-1e145bccb391,
abstract = {{<p>Background: Previous studies on contact allergy to diabetes medical devices (MDs) are based on patients referred for patch testing due to suspected allergic contact dermatitis. Objectives: To present real-world data on contact allergy to MD allergens among diabetes MD users. To suggest a MD patch test series. Methods: Adults with type 1 diabetes using diabetes MDs followed up at two endocrinology departments were invited to be patch tested with a novel MD patch test series. Results: Of the 204 participants (114 with skin rash to diabetes MDs, 90 without), 16.2% were positive to allergens found in diabetes MDs. The prevalence was significantly higher in those with skin rash to diabetes MDs versus without (28.1% vs. 1.1%; adjusted p-value < 0.001). For allergens found in diabetes MDs, the highest contact allergy rates were seen to isobornyl acrylate (10.3%), N,N-dimethylacrylamide (4.9%), 2-hydroxyethyl acrylate (3.4%), and dicyclohexylmethane-4,4′-diisocyanate (2.9%). Conclusions: Among diabetes MD users, the prevalence of contact allergy to MD allergens was remarkably high. 2-hydroxyethyl acrylate has not previously been reported as a culprit allergen in diabetes MDs, which underlines the importance of repeated chemical analyses and continuous update of the MD series. A better prevention of MD-related contact allergies is called for.</p>}},
author = {{Ulriksdotter, Josefin and Mowitz, Martin and Sukakul, Thanisorn and Bruze, Magnus and Hamnerius, Nils and Svedman, Cecilia}},
issn = {{0105-1873}},
keywords = {{contact allergy; continuous glucose monitoring; insulin infusion systems; type 1 diabetes}},
language = {{eng}},
publisher = {{Wiley-Blackwell}},
series = {{Contact Dermatitis}},
title = {{Patch Testing in Individuals With Diabetes Using Medical Devices. Part 2—Contact Allergy to Medical Device Allergens and New Patch Test Recommendations}},
url = {{http://dx.doi.org/10.1111/cod.70149}},
doi = {{10.1111/cod.70149}},
year = {{2026}},
}